$KTTA News

Last published 1w ago

1w agoKTTA KTTAWPasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)GlobeNewswire— FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies. — MIAMI, Nov. 03, 2026
2w agoKTTA KTTAWPasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026GlobeNewswireMIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation
2w agoKTTA KTTAWPasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026GlobeNewswire-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over
1mo agoKTTA KTTAWPasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis ConferenceGlobeNewswire- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation -
2mo agoKTTA KTTAWPasithea Therapeutics Announces Participation in Two September 2026 Investor ConferencesGlobeNewswire-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September
3mo agoKTTA KTTAWPasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026GlobeNewswire-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October
4mo agoKTTA KTTAWPasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision SummitGlobeNewswireMIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation
4mo agoKTTA KTTAWPasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol ExpansionGlobeNewswire-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related
4mo agoKTTA KTTAWPasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical TrialGlobeNewswire-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA)
4mo agoKTTA KTTAWPasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF ConferenceGlobeNewswire-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are
5mo agoKTTA KTTAWPasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)GlobeNewswireMIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
6mo agoKTTA KTTAWPasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerGlobeNewswireMIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
6mo agoKTTA KTTAWPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)GlobeNewswireMIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
7mo agoKTTA KTTAWPasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant MorbidityGlobeNewswireMIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
8mo agoKTTA KTTAWPasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswire– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the
10mo agoKTTA KTTAWPasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release TimelinesGlobeNewswireMIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK
11mo agoKTTA KTTAWPasithea Therapeutics Announces Closing of $60 Million Public Offering of Common StockGlobeNewswireExtends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital
11mo agoKTTA KTTAWPasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common StockGlobeNewswireExtends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management
11mo agoKTTA KTTAWPasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALSGlobeNewswire-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomarker-driven
11mo agoKTTA KTTAWPasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataGlobeNewswire-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio <2. Achieved
11mo agoKTTA KTTAWPasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsGlobeNewswire-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with improved
11mo agoKTTA KTTAWPasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer StudyGlobeNewswire-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line
1y agoKTTA KTTAWPasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsGlobeNewswireMIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK
1y agoKTTA KTTAWPasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsGlobeNewswireMIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor
1y agoKTTA KTTAWPasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsGlobeNewswire-- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pasithea
1y agoKTTA KTTAWPasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireMIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
1y agoKTTA KTTAWPasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireMIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
1y agoKTTA KTTAWPasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsGlobeNewswireMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor
1y agoKTTA KTTAWPasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory BoardGlobeNewswireMIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
1y agoKTTA KTTAWPasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025GlobeNewswire-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma,
1y agoKTTA KTTAWPasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesGlobeNewswire-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway
1y agoKTTA KTTAWPasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteGlobeNewswire-- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas
1y agoKTTA KTTAWPasithea Therapeutics Announces Closing of $5 Million Public OfferingGlobeNewswireMIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. ("Pasithea," or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK
1y agoKTTA KTTAWPasithea Therapeutics Announces Pricing of $5 Million Public OfferingGlobeNewswireMIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. ("Pasithea," or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK
1y agoKTTA KTTAWPasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004GlobeNewswire-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor
1y agoKTTA KTTAWPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsGlobeNewswireMIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
1y agoKTTA KTTAWPasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingGlobeNewswireMIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
1y agoKTTA KTTAWPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerGlobeNewswire– SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT's) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics
1y agoKTTA KTTAWPasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer ConferenceGlobeNewswire-- Conference taking place on March 27-29, 2025 in New Orleans -- -- CAGLA NeauxCancer Conference is a leading global forum in oncology -- MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp.
1y agoKTTA KTTAWPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerGlobeNewswireSRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT's) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE
1y agoKTTA KTTAWPasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4GlobeNewswire-- Interim data from Cohort 4 expected Q1 2025 -- MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing
1y agoKTTA KTTAWPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerGlobeNewswire-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities (DLTs) observed to date -- -- No rash observed to date -- MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) --
2y agoKTTA KTTAWPasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswireMIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
2y agoKTTA KTTAWPasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced CancerGlobeNewswire-- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No treatment-related adverse events
2y agoKTTA KTTAWPasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity StudiesGlobeNewswireMIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
2y agoKTTA KTTAWPasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardGlobeNewswireMIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
2y agoKTTA KTTAWPasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company") a clinical-stage biotechnology company developing PAS-004, a
2y agoKTTA KTTAWPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialGlobeNewswireMIAMI, June 13, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor,
2y agoKTTA KTTAWPasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingGlobeNewswire-- PAS-004 inhibition of in vitro NRAS cell lines does not plateau in contrast to approved MEK inhibitors -- -- PAS-004 inhibition of in vitro NRAS cell lines is greater than selumetinib and binimetinib and
2y agoKTTA KTTAWPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a